Sign In
Last checked at 
3 Aug 2021 13:16
The following amendment has been made to the 'Result of AGM' announcement released on 3 August 2021 at 12:32 under RNS No 4383H. The percentage of votes cast in favour of resolution 1 has been corrected to reflect 99.96%. All other details remain unchanged. The full amended text is shown below.
Syncona Limited
Result of Annual General Meeting and Retirement of Director
3 August 2021
At the Annual General Meeting of Syncona Limited (the "Company") held today, all Resolutions as set out in the 'Notice of the 2021 Annual General Meeting' dated 1 July 2021 sent to shareholders of the Company (the "Notice") were duly passed.
Resolutions 1 to 13 were proposed as Ordinary Resolutions. Resolution 14 was proposed as a Special Resolution and Resolution 15 was proposed as an Extraordinary Resolution.
Details of the proxy voting results, which should be read alongside the Notice, are noted below:
No | Resolution | For | Discretion | Against | Abstain (withheld) |
1 | Receive and consider the Annual Audited Financial Statements of the Company for the year ended 31 March 2021, together with the Reports of the Directors and Auditors thereon | 485,406,865 (99.96%) | 0 (0%) | 189,929 (0.04%) | 2,418
|
2 | Re-appointment of Deloitte LLP (Guernsey Branch) as Auditors | 485,338,006 (99.99%) | 0 (0%) | 68,688 (0.01%) | 192,518 |
3 | Authorise the Directors to determine the remuneration of the Auditors | 485,591,907 (99.99%) | 0 (0%) | 7,305 (0.01%) | 0 |
4 | Re-elect Melanie Gee as a Director | 463,380,320 (96.42%) | 0 (0%) | 17,192,066 (3.58%) | 5,026,826 |
5 | Elect Virginia Holmes as a Director | 485,588,541 (99.99%) | 0 (0%) | 4,756 (0.01%) | 5,915 |
6 | Re-elect Rob Hutchinson as a Director | 485,552,870 (99.99%) | 0 (0%) | 39,924 (0.01%) | 6,418 |
7 | Re-elect Nigel Keen as a Director | 485,550,870 (99.99%) | 0 (0%) | 41,924 (0.01%) | 6,418
|
8 | Re-elect Kemal Malik as a Director | 485,552,123 (99.99%) | 0 (0%) | 38,756 (0.01%) | 8,333 |
9 | Re-elect Nicholas Moss as a Director | 485,550,870 (99.99%) | 0 (0%) | 41,924 (0.01%) | 6,418 |
10 | Re-elect Gian Piero Reverberi as a Director | 485,554,038 (99.99%) | 0 (0%) | 38,756 (0.01%) | 6,418 |
11 | Approve the report on implementation of the Remuneration Policy for Non-Executive Directors | 483,970,337 (99.67%) | 0 (0%) | 1,618,992 (0.33%) | 9,883 |
12 | Authority to allot and issue shares | 484,125,810 (99.7%) | 0 (0%) | 1,464,359 (0.3%) | 9,043 |
13 | Increase the maximum aggregate amount of fees for all the Board collectively in any financial year from £500,000 to £1,000,000 | 468,468,131 (96.62%) | 0 (0%) | 16,378,940 (3.38%) | 752,141 |
14 | Authorise the Company to purchase its own shares | 485,356,393 (99.94%) | 11,377 (0.01%) | 226,656 (0.05%) | 4,786 |
15 | Disapply pre-emption rights | 485,561,682 (99.98%) | 11,377 (0.01%) | 19,631 (0.01%) | 6,522 |
A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.
In addition, the Company confirms that, in line with the announcement made previously, Tom Henderson has retired from the Board of the Company with effect from the close of the AGM.
Melanie Gee, Chair of Syncona, commented:
"On behalf of the Board and all our stakeholders, I would like to thank Tom for his significant contribution to both Syncona and the Syncona Foundation over the last nine years. Tom was instrumental in the creation of The Battle Against Cancer Investment Trust (BACIT) in 2012, an innovative investment company that persuaded underlying fund managers to provide their services without charging a fee, and alongside that donated a percentage of its net asset value each year to charity. Tom also played an important role in BACIT's merger with Syncona Partners in 2016, thereby forming the Syncona of today.
Tom remains the Chair of the Foundation, to which Syncona continues to make significant donations, and we look forward to continuing to benefit from his expertise and passion to support the charities to which the Foundation donates and the individuals and families that they support."
In accordance with the Listing Rule 9.6.2, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the Financial Conduct Authority via the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The full text of the resolutions can be found in the Notice, which is available on the Company's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/.
Enquiries
Syncona LimitedAnnabel Clay/Fergus WittTel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com.
About Syncona:
Syncona's purpose is to invest to extend and enhance human life. We do this by founding, building and funding a portfolio of global leaders in life science, to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to found, build and fund companies around exceptional science to create a dynamic portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or few treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
Follow the stocks
